An announcement from Vivani Medical (VANI) is now available.
Vivani Medical, Inc. has expanded its Board of Directors from five to six members and appointed Daniel Bradbury to fill the new position. Bradbury brings extensive experience to the board, including his previous role as CEO of Amylin Pharmaceuticals until its acquisition by Bristol-Myers Squibb, and his current involvement with several other biopharmaceutical companies and nonprofit organizations. He will serve on the Board and the Audit Committee until the 2025 annual stockholders’ meeting, receiving compensation in line with the company’s policy for non-employee directors.
For detailed information about VANI stock, go to TipRanks’ Stock Analysis page.
